D. Kathleen Laporte's Insider Trades & SAST Disclosures
D. Kathleen Laporte's most recent trade in Precipio Inc was a trade of 2,232 Common Stock done at an average price of $5.6 . Disclosure was reported to the exchange on April 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern D. Kathleen Laporte.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Precipio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 5.60 per share. | 15 Apr 2025 | 2,232 | 12,303 (0%) | 0% | 5.6 | 12,499 | Common Stock |
| CERo Therapeutics Holdings... | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 17,923 | 17,923 | - | - | Stock Option (Right to Buy) | |
| CERo Therapeutics Holdings... | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 127,500 | 255,000 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Laporte Kathleen D. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 12,767 | 0 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Laporte D. Kathleen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Kathleen D. Laporte | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 5,431 | 0 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Laporte D. Kathleen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 5,431 | 5,431 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Laporte D. Kathleen | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 1,947 | 0 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | D. Kathleen Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 1,947 | 1,947 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 56,400 | 56,400 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2025 | 1,000 | 1,000 | - | - | Stock Option (Right to Buy) | |
| CERo Therapeutics Holdings... | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2024 | 127,500 | 127,500 | - | - | Stock Option (Right to Buy) | |
| CERo Therapeutics Holdings... | Kathleen D. Laporte | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2024 | 965,997 | 965,997 | - | - | Common Stock | |
| CERo Therapeutics Holdings... | Kathleen D. Laporte | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2024 | 50 | 0 | - | - | Series A Convertible Preferred Stock | |
| Precipio Inc | D. Kathleen Laporte | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Aug 2024 | 2,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Laporte Kathleen D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2024 | 2,000 | 2,000 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Aug 2024 | 1,250 | 0 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Aug 2024 | 1,250 | 0 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | D. Laporte Kathleen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2024 | 1,250 | 1,250 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | D. Laporte Kathleen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2024 | 1,250 | 1,250 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | D. Kathleen Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2024 | 375 | 375 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | D. Kathleen Laporte | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Aug 2024 | 375 | 0 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Laporte D. Kathleen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2024 | 250 | 250 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Laporte Kathleen D. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Aug 2024 | 250 | 0 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2024 | 200 | 200 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | D. Kathleen Laporte | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Aug 2024 | 200 | 0 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2024 | 188 | 188 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Aug 2024 | 188 | 0 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | D. Kathleen Laporte | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Aug 2024 | 75 | 0 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Laporte D. Kathleen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2024 | 75 | 75 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | D. Laporte Kathleen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2024 | 70 | 70 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Aug 2024 | 70 | 0 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Aug 2024 | 28 | 0 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | D. Laporte Kathleen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2024 | 28 | 28 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 1,000 | 1,000 | - | - | Stock Option (Right to Buy) | |
| Bolt Biotherapeutics Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 6.70 per share. | 15 Apr 2024 | 9,693 | 10,071 (0%) | 0% | 6.7 | 64,943 | Common Stock |
| CERo Therapeutics Holdings... | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 112,500 | 112,500 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| CERo Therapeutics Holdings... | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 50 | 50 | - | - | Series A Convertible Preferred Stock | |
| 89bio Inc | D. Laporte Kathleen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 45,150 | 45,150 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Kathleen D. Laporte | Director | Sale of securities on an exchange or to another person at price $ 18.80 per share. | 17 Jul 2023 | 12,500 | 0 (0%) | 0% | 18.8 | 235,000 | Common Stock |
| 89bio Inc | Kathleen D. Laporte | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Kathleen D. Laporte | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.64 per share. | 17 Jul 2023 | 12,500 | 12,500 (0%) | 0% | 2.6 | 33,000 | Common Stock |
| 89bio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 27,400 | 27,400 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Bolt Biotherapeutics Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Bolt Biotherapeutics Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Bolt Biotherapeutics Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Bolt Biotherapeutics Inc | Kathleen D. Laporte | Director | Purchase of securities on an exchange or from another person at price $ 20.00 per share. | 09 Feb 2021 | 1,200 | 1,200 | - | 20 | 24,000 | Common Stock |
| Precipio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Precipio Inc | Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2020 | 4,000 | 4,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges